Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 126 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Amlodipine besylate Clear all
Completed Not applicable Interventional Results available

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

NCT02121041
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine, Chlorthalidone, Losartan
Drug
Lead sponsor
Anthony J Viera, MD, MPH
Other
Eligibility
30 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Not applicable Interventional Results available

Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension

NCT02412761
View directory record Official record
Conditions
Essential Hypertension
Interventions
Lisinopril, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Years to 22 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 4 Interventional Results available

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

NCT03657550
View directory record Official record
Conditions
Hypertension
Interventions
Levamlodipine, Amlodipine, Amlodipine, Levamlodipine
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fasting Conditions

NCT00602017
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

NCT00523549
View directory record Official record
Conditions
Hypertension, Diastolic Dysfunction
Interventions
valsartan, amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
USA, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 6, 2026, 9:00 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

NCT01271374
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan, losartan and HCTZ
Drug
Lead sponsor
InVasc Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tucker, Georgia
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 2 Interventional Results available

Amlodipine Plus Botulinum Toxin for Focal Dystonia

NCT00015457
View directory record Official record
Conditions
Focal Dystonia
Interventions
Amlodipine plus Botulinum toxin
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amlodipine Tablets Under Fasting Conditions

NCT00775905
View directory record Official record
Conditions
Healthy
Interventions
amlodipine 10 mg tablet
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension

NCT00142584
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol (NEB), Metoprolol (MET)
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

NCT03354143
View directory record Official record
Conditions
Hypertension
Interventions
Standard Care, Intensive Treatment
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 6, 2026, 9:00 AM EDT
Terminated Phase 1 Interventional Results available

Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity

NCT04329806
View directory record Official record
Conditions
Obesity-Associated Insulin Resistance
Interventions
Moxonidine 0.2 MG, Amlodipine 5 MG
Drug
Lead sponsor
Italo Biaggioni
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Avanafil and Enalapril or Amlodipine

NCT01117038
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
avanafil and enalapril, avanafil and amlodipine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
40 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2011 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

NCT00649389
View directory record Official record
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
228
States / cities
Birmingham, Alabama • Columbiana, Alabama • Gulf Shores, Alabama + 225 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

NCT04518306
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
Drug
Lead sponsor
George Medicines PTY Limited
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 6, 2026, 9:00 AM EDT
Completed No phase listed Observational

Genetics of Hypertension Associated Treatments (GenHAT)

NCT00006294
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions
Chlorthalidone, Lisinopril, Amlodipine, Doxazosin
Drug
Lead sponsor
Donna Arnett, 257-5678
Other
Eligibility
55 Years and older
Enrollment
37,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 4 Interventional Results available

Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

NCT02046395
View directory record Official record
Conditions
Type 2 Diabetes, Hypertension
Interventions
amlodipine, hydralazine, terazosin or hydrochlorothiazide
Drug
Lead sponsor
Tulane University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT00877929
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan 80, Amlodipine 10
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
15
States / cities
Long Beach, California • Tustin, California • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 6, 2026, 9:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

Sympathetic Mechanisms in Obesity-Crossover Design

NCT05312892
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Amlodipine, Moxonidine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension

NCT00591266
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil and amlodipine, Amlodipine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 6, 2026, 9:00 AM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

NCT01368536
View directory record Official record
Conditions
Hypertension, Stage 2 Hypertension, Diabetes
Interventions
Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
95
States / cities
Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 6, 2026, 9:00 AM EDT
Completed Phase 3 Interventional Results available

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension

NCT00281580
View directory record Official record
Conditions
Hypertension
Interventions
Amlodipine 5 mg, Placebo, Telmisartan 20 mg, Telmisartan 40 mg, Amlodipine 10 mg, Telmisartan 80 mg, Amlodipine 2.5 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
101
States / cities
Fairhope, Alabama • Huntsville, Alabama • Chandler, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 6, 2026, 9:00 AM EDT
Withdrawn Phase 4 Interventional

Treating Nocturnal Hypertension and Nocturia in African American Men

NCT03319823
View directory record Official record
Conditions
High Blood Pressure
Interventions
Thiazide Treatment Group, Intensified Thiazide Treatment Group, Combination Medication Treatment Group
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 59 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 6, 2026, 9:00 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Hypertension in Young Adults Trial

NCT05370599
View directory record Official record
Conditions
Hypertension
Interventions
Anti-hypertensive agent: amlodipine, Anti-hypertensive agent: Chlorthalidone, Anti-hypertensive agent: Losartan, Home BP monitoring with cuffed device, Home BP monitoring with cuffed device + BP patch, Home BP monitoring with cuffed device + BP watch
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 6, 2026, 9:00 AM EDT